VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Reports 2017 First Quarter Financial Results
VIVUS Focuses on its Strategic Initiative to Acquire New Product Pipeline
View HTML
Toggle Summary VIVUS Announces Date of 2017 First Quarter Business Update and Financial Results Teleconference
CAMPBELL, CA -- (Marketwired) -- 04/25/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2017 after the NASDAQ Market closes on Wednesday, May 3, 2017 . The company will conduct a conference call and an
View HTML
Toggle Summary VIVUS, Inc. Reacquires STENDRA(R) (Avanafil) Commercial Rights from Sanofi
VIVUS to Receive Commercial Rights to Africa, the Middle East, Turkey and the Commonwealth of Independent States, Including Russia
View HTML
Toggle Summary VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results
Strong Cash Position Enables Strategic Initiative to Acquire New Product Pipeline
View HTML
Toggle Summary VIVUS Announces Date of 2016 Fourth Quarter Business Update and Financial Results Teleconference
CAMPBELL, CA -- (Marketwired) -- 02/28/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2016 after the NASDAQ Market closes on Wednesday, March 8, 2017 . The company will conduct a conference call and an
View HTML
Toggle Summary VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
CAMPBELL, CA , and SAN CARLOS, CA -- (Marketwired) -- 01/09/17 -- VIVUS, Inc. ( NASDAQ : VVUS) and Selten Pharma, Inc. , announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary
View HTML